BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Epcoritamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Epcoritamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06287398-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06287398)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASC
 T & Epcor Consolidation in Patients With Relapsed LBCL\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06287398
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672705-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT06672705)
DESCRIPTION:Epcoritamab\, phase 1\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Ly
 mphoproliferative Disorders\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06672705
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06723457-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06723457)
DESCRIPTION:Epcoritamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Epcorita
 mab and Lenalidomide in Treating Patients With Refractory or Relapsed Immu
 nodeficiency-Related Large B-Cell Lymphoma\nEstimated primary completion: 
 18 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epc
 oritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06723457
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451810-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05451810)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Admini
 stered in the Outpatient Setting in Adult Participants With Relapsed or Re
 fractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma\nEs
 timated primary completion: March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05451810
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510491-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06510491)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Epcoritamab in Previously Treate
 d WM\nEstimated primary completion: 30 April 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06510491
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510361-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06510361)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: A Phase 2 
 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zon
 e Lymphoma Not Accomplishing a Complete Response With Upfront Therapy\nEst
 imated primary completion: 1 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06510361
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05578976)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcori
 tamab Combined With Intravenous and Oral Rituximab\, Cyclophosphamide\, Do
 xorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or R-CHOP 
 in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (
 DLBCL)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676033-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT06676033)
DESCRIPTION:Epcoritamab\, phase 1.\nStudy: Epcoritamab in Chronic Lymphocyt
 ic Leukemia and Richter Syndrome\nEstimated primary completion: 1 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06676033
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108998-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07108998)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Study of Epcoritamab as a Consol
 idation Therapy in CLL/SLL\nEstimated primary completion: 1 July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07108998
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112847-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06112847)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Lenalidomi
 de and Epcoritamab for the Treatment of Previously Untreated Follicular Ly
 mphoma\nEstimated primary completion: 10 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06112847
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536049-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT06536049)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory A
 ggressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 536049
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects Wit
 h Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451652-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07451652)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Low Dose Epcoritamab Plus GemOx in R/R DLBCL\nEstimated primary completion
 : September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epc
 oritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07451652
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B
 -cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 663347
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201248-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT05201248)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: A Study to Evaluate Adverse Ev
 ents and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Mo
 notherapy or Combined With Standard of Care Therapies in Adult Participant
 s in China With B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion:
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcori
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05201248
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06458439-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06458439)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab-CAR T Cells for Large B-cell Lymphomas\nEstimated primary comp
 letion: October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06458439
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090539-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT06090539)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: A Study to Assess BMS-986458 A
 lone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory N
 on-Hodgkin Lymphomas\nEstimated primary completion: 28 October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06090539
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852717-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20271124
DTEND;VALUE=DATE:20271125
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05852717)
DESCRIPTION:Epcoritamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Safety a
 nd Efficacy of Epcoritamab With Gemcitabine\, Dexamethasone\, and Cisplati
 n (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma\
 nEstimated primary completion: 24 November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05852717
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: Safety and Efficacy Study of E
 pcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukem
 ia and Richter's Syndrome\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931652-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06931652)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the C
 NS Treated With Lenalidomide and Rituximab\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcorit
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06931652
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05783609-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05783609)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Epcoritama
 b and Rituximab for First-line Follicular Lymphoma\nEstimated primary comp
 letion: February 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05783609
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tabl
 ets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemci
 tabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 8658
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814001-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07814001)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma
  After Second-Line CAR T-cell Therapy\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781400
 1
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06905509)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologo
 us Hematopoietic Cell Transplant for the Treatment of Relapsed or Refracto
 ry Large B-cell Lymphoma\nEstimated primary completion: 1 July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045247-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06045247)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Ol
 der Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With N
 ewly Diagnosed Diffuse Large B-cell Lymphoma\nEstimated primary completion
 : 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcor
 itamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06045247
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082868-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT07082868)
DESCRIPTION:Epcoritamab\, phase 1.\nStudy: A Study of Epcoritamab and Ibrut
 inib in People With Central Nervous System Lymphoma (CNSL)\nEstimated prim
 ary completion: August 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/epcoritamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07082868
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588698-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07588698)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Ho
 dgkin Lymphoma\nEstimated primary completion: 31 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07588698
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06447376-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT06447376)
DESCRIPTION:Epcoritamab\, phase 1.\nStudy: Study of Cytokine Release Syndro
 me Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab\nEstimat
 ed primary completion: 1 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06447376
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819214-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07819214)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Epcoritamab as Consolidation The
 rapy for High-Risk Pts w/CLL on BTKI\nEstimated primary completion: Octobe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07819
 214
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883135-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07883135)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Bispecific Antibody-Based Holdin
 g/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas\nEstimated 
 primary completion: 1 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07883135
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796998-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06796998)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Epcoritamab in Patients With New
 ly Diagnosed Marginal Zone Lymphoma (MZL)\nEstimated primary completion: 1
 5 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcor
 itamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06796998
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05206357-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT05206357)
DESCRIPTION:Epcoritamab\, phase 1.\nStudy: Study of the Adverse Events and 
 Change in Disease State of Pediatric Participants (and Young Adults Betwee
 n the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neo
 plasms Receiving Subcutaneous (SC) Injections of Epcoritamab\nEstimated pr
 imary completion: November 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05206357
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783594-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07783594)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Randomized
  Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously
  Untreated Low Tumor Burden FollicularLymphoma\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07783594
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03625037-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT03625037)
DESCRIPTION:Epcoritamab\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: First-
 in-Human (FIH) Trial in Patients With Relapsed\, Progressive or Refractory
  B-Cell Lymphoma\nEstimated primary completion: January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03625037
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05791409-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT05791409)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: Venetoclax Treatment (26 Cycle
 s) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or 
 Refractory CLL or SLL\nEstimated primary completion: March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05791409
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848765-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05848765)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Relapsed F
 ollicular Lymphoma Randomised Trial Against Standard ChemoTherapy\nEstimat
 ed primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05848765
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218510-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20290608
DTEND;VALUE=DATE:20290609
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07218510)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Venetoclax and Obinutuzumab Foll
 owed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leu
 kemia and Small Lymphocytic Lymphoma\, LonGEVity Trial\nEstimated primary 
 completion: 8 June 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07218510
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365306-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07365306)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab\, Rituximab\, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage
  Therapy Before Autologous Stem Cell Transplant for the Treatment of Relap
 sed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion
 : 15 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ep
 coritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07365306
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05409066)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Follicular Lymphoma\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05409066
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238648-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06238648)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients 
 Not in Complete Remission After CD19-directed CAR-T Therapy\nEstimated pri
 mary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06238648
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738887-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07738887)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Epcoritamab Plus Venetoclax Plus
  Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterat
 ions\nEstimated primary completion: 31 December 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07738887
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563596-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06563596)
DESCRIPTION:Epcoritamab\, phase 2\, Follicular Lymphoma.\nStudy: Epco\, Zan
 u\, Ritux for R/R FL or MZL\nEstimated primary completion: 1 March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06563596
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197307-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07197307)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Di
 ffuse Large B-cell Lymphoma (DLBCL)\nEstimated primary completion: 30 Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07197
 307
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917780-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20300515
DTEND;VALUE=DATE:20300516
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07917780)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: A Trial to Evaluate the Efficacy
  of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatmen
 t of Patients With DLBCL-type Richter Transformation\nEstimated primary co
 mpletion: 15 May 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07917780
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07097363-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07097363)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab With Dose Adjusted Etoposide\, Cyclophosphamide\, Vincristine\
 , Doxorubicin\, Prednisone and Rituximab (EPOCH-R) for the Treatment of Ag
 gressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 May
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070973
 63
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528352-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT07528352)
DESCRIPTION:Epcoritamab\, phase 1\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Rel
 apsed/Refractory DLBCL\nEstimated primary completion: June 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07528352
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714421-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20301008
DTEND;VALUE=DATE:20301009
SUMMARY:Epcoritamab: Phase 1 readout est. (NCT07714421)
DESCRIPTION:Epcoritamab\, phase 1\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell 
 Lymphoma in Elderly or Unfit Patients\nEstimated primary completion: 8 Oct
 ober 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 714421
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860775-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07860775)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Treatment of Chronic Lymphocytic
  Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination 
 With Epcoritamab if the Disease Comes Back After Previous Treatment.\nEsti
 mated primary completion: 15 October 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07860775
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882173-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07882173)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Epcoritamab as Consolidative The
 rapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a 
 Bruton Tyrosine Kinase Inhibitor (BTKi)\nEstimated primary completion: 1 N
 ovember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcorit
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07882173
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919939-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20310107
DTEND;VALUE=DATE:20310108
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06919939)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refract
 ory Large B-cell Lymphoma\nEstimated primary completion: 7 January 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06919939
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662928-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07662928)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: Epcoritamab in Combination With 
 Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL)\, The BEDROCK St
 udy\nEstimated primary completion: 30 May 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07662928
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283679-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT07283679)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: Trial of ONC-PluReceptor NK Ce
 lls With Epcoritamab and Tafasitamab for Patients With Recurrent or Refrac
 tory B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 Septemb
 er 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 3679
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126236-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07126236)
DESCRIPTION:Epcoritamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Response
 -adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy 
 of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma\n
 Estimated primary completion: 27 December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07126236
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05283720)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: A Study to Evaluate Adverse Even
 ts and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Comb
 ination With Oral and Intravenous Anti-Neoplastic Agents in Adult Particip
 ants With Non-Hodgkin Lymphoma\nEstimated primary completion: November 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05283720
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-10986@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Previously Untreated Follicular Lymphoma\nEsti
 mated primary completion: November 2037. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
